Bristol Myers Squibb reports positive ACTION-1 trial results
Bristol Myers Squibb said the interim ACTION-1 study met its primary endpoint, showing improved progression-free survival for patients receiving RYZ101.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Reuters reports that Bristol-Myers Squibb announced positive topline findings from the interim analysis of ACTION-1, a Phase 3 study evaluating RYZ101, RayzeBio’s radiopharmaceutical therapy, in patients with GEP-NETS.
The trial met its primary endpoint, with improved progression-free survival reported among patients. Bristol-Myers Squibb also said the safety findings were consistent with the previously known safety profile of RYZ101.
why it matters
For markets, the announcement indicates that the program has reached a key clinical milestone and keeps attention focused on RYZ101’s development prospects. The report provides topline interim findings but no additional numerical results.
instruments
sources
- Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS — Reuters, 12 October 2026 at 13:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗